Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.
Ollin Biosciences has raised $330.0M in total funding. The most recent round was Series B. The last funding was announced in June 2026.
Ollin Biosciences's investors include RA Capital Management, ARCH Venture Partners, Mubadala Capital, TCG Crossover, T. Rowe Price.
Ollin Biosciences is headquartered in Austin, United States.
Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.
Ollin Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ollin Biosciences — Funding & Investors." VCBacked, June 24, 2026, https://www.vcbacked.co/company/ollin-biosciences. Accessed October 19, 2026.
VCBacked. (2026). Ollin Biosciences — Funding & Investors. Retrieved October 19, 2026, from https://www.vcbacked.co/company/ollin-biosciences
{{cite web |title=Ollin Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/ollin-biosciences |website=VCBacked |access-date=October 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated